Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis

The pathophysiology of Alzheimer’s disease (AD) is multifactorial with characteristic extracellular accumulation of amyloid-beta (Aβ) and intraneuronal aggregation of hyperphosphorylated tau in the brain. Development of disease-modifying treatment for AD has been challenging. Recent studies suggest that deleterious alterations in neurovascular cells happens in parallel with Aβ accumulation, inducing tau pathology and necroptosis. Therefore, therapies targeting cellular Aβ and tau pathologies may provide a more effective strategy of disease intervention. Tetramethylpyrazine nitrone (TBN) is a nitrone derivative of tetramethylpyrazine, an active ingredient from Ligusticum wallichii Franchat (Chuanxiong). We previously showed that TBN is a potent scavenger of free radicals with multi-targeted neuroprotective effects in rat and monkey models of ischemic stroke. The present study aimed to investigate the anti-AD properties of TBN. We employed AD-related cellular model (N2a/APPswe) and transgenic mouse model (3×Tg-AD mouse) for mechanistic and behavioral studies. Our results showed that TBN markedly improved cognitive functions and reduced Aβ and hyperphosphorylated tau levels in mouse model. Further investigation of the underlying mechanisms revealed that TBN promoted non-amyloidogenic processing pathway of amyloid precursor protein (APP) in N2a/APPswe in vitro. Moreover, TBN preserved synapses from dendritic spine loss and upregulated synaptic protein expressions in 3×Tg-AD mice. Proteomic analysis of 3×Tg-AD mouse hippocampal and cortical tissues showed that TBN induced neuroprotective effects through modulating mitophagy, MAPK and mTOR pathways. In particular, TBN significantly upregulated PINK1, a key protein for mitochondrial homeostasis, implicating PINK1 as a potential therapeutic target for AD. In summary, TBN improved cognitive functions in AD-related mouse model, inhibited Aβ production and tau hyperphosphorylation, and rescued synaptic loss and neuronal damage. Multiple mechanisms underlie the anti-AD effects of TBN including the modulation of APP processing, mTOR signaling and PINK1-related mitophagy.

[1]  M. Beal,et al.  The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  L. Jiménez‐Díaz,et al.  Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review , 2021, Ageing Research Reviews.

[3]  Mayank Gupta,et al.  Aducanumab as a Novel Treatment for Alzheimer’s Disease: A Decade of Hope, Controversies, and the Future , 2021, Cureus.

[4]  M. Sabbagh,et al.  The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis , 2019, Alzheimer's & Dementia.

[5]  Bin Zhang,et al.  Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation , 2019, bioRxiv.

[6]  Yuqiang Wang,et al.  Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease , 2019, Experimental neurobiology.

[7]  Yuqiang Wang,et al.  Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment. , 2018, Journal of proteome research.

[8]  T. Cassano,et al.  Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[9]  Irving E. Vega,et al.  Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease. , 2018, Current Alzheimer research.

[10]  G. Juhász,et al.  Early Presymptomatic Changes in the Proteome of Mitochondria-Associated Membrane in the APP/PS1 Mouse Model of Alzheimer’s Disease , 2018, Molecular Neurobiology.

[11]  Wei Liu,et al.  Neuroprotective Effect and Mechanism of Action of Tetramethylpyrazine Nitrone for Ischemic Stroke Therapy , 2018, NeuroMolecular Medicine.

[12]  M. Geng,et al.  Alzheimer’s disease hypothesis and related therapies , 2018, Translational Neurodegeneration.

[13]  S. Campello,et al.  Mitophagy in neurodegenerative diseases , 2017, Neurochemistry International.

[14]  L. Lue,et al.  PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[15]  Huan Chen,et al.  iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer’s Disease , 2017, Current Alzheimer research.

[16]  B. Ueberheide,et al.  Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease , 2017, Acta Neuropathologica.

[17]  M. Z. Cader,et al.  Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms , 2017, Trends in Neurosciences.

[18]  Z. Leonenko,et al.  Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. , 2017, Journal of Alzheimer's disease : JAD.

[19]  Yuqiang Wang,et al.  Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy , 2016, Scientific Reports.

[20]  M. Sastre,et al.  Mechanisms of Aβ Clearance and Degradation by Glial Cells , 2016, Front. Aging Neurosci..

[21]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[22]  Eric Karran,et al.  The Cellular Phase of Alzheimer’s Disease , 2016, Cell.

[23]  Azza A Ali,et al.  Alzheimer's Disease: Pathophysiology, Hypotheses and Treatment Strategies , 2016 .

[24]  N. Jha,et al.  Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. , 2015, Journal of Alzheimer's disease : JAD.

[25]  Sonia Gandhi,et al.  Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson’s disease , 2014, Nature Cell Biology.

[26]  S. Love,et al.  A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.

[27]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[28]  N. Belyaev,et al.  Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. , 2008, Current Alzheimer research.

[29]  J. Buxbaum,et al.  Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease , 2007, Neurobiology of Aging.

[30]  M. Higuchi,et al.  Metabolism of amyloid-β peptide and Alzheimer's disease , 2005 .

[31]  N. Nalivaeva,et al.  Targeting Amyloid‐Degrading Enzymes as Therapeutic Strategies in Neurodegeneration , 2004, Annals of the New York Academy of Sciences.

[32]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[33]  D. Butterfield,et al.  Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration , 2003, Journal of neurochemistry.

[34]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[35]  Mark S. Shearman,et al.  Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .